The global bispecific antibodies market was valued at USD 8.77 Billion in 2024, driven by the rising incidence of chronic diseases across the globe. The market is anticipated to grow at a CAGR of 36.81% during the forecast period of 2025-2034, with the values likely to reach USD 201.45 Billion by 2034.
Base Year
Historical Year
Forecast Year
Value in USD Billion
2025-2034
Bispecific Antibodies Market Outlook
*this image is indicative*
A bispecific monoclonal antibody is a protein that can attach to two distinct antigens or epitopes. They can activate immune cells, disrupt signaling, improve immune system function and regulate immune reactions. Bispecific antibodies offer versatility and specificity, showing promise in treating diverse diseases and influencing the future of individualized healthcare.
Rising Incidence of Chronic Diseases to Boost the Market Growth
The increasing prevalence of chronic illnesses like cancer and autoimmune conditions is fueling market expansion. According to the Centers for Disease Control and Prevention, 6 out of every 10 Americans have at least one chronic illness, and bispecific antibodies are effectively addressing medical needs.
Technological Advancements to Drive the Bispecific Antibodies Market Value
The market is experiencing growth due to technological advancements, like using a DNA nanotechnology platform. This leads to more effective progress by offering an understanding of how spatial arrangement impacts their work, essential for speeding up research and improvement.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Application:
Market Breakup by Drugs:
Market Breakup by Route of Administration:
Market Breakup by End User:
Market Breakup by Region:
Segmentation Based on End User to Witness Substantial Growth
Based on the end user, the market is segmented into hospitals, specialty clinics, and others. Hospitals are poised to dominate the market, as their state-of-the-art medical facilities and specialized oncology units allow for the delivery of innovative therapies for cancers targeted by bispecific antibodies, showcasing their key role in healthcare and biopharmaceutical development.
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In North America, collaborations between pharmaceutical companies and academic institutions, strong investment in research and development, and an emphasis on personalized medicine, particularly in the field of bispecific antibodies, are expected to drive the market value in the forecast period.
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Amgen is a global biopharmaceutical company, based in Thousand Oaks, CA, that is at the forefront of the bispecific antibody market with its BiTE® molecules. These fusion proteins link T cells with tumor cells, releasing cytotoxic substances for treating cancer.
Roche, a healthcare company from Switzerland, saw a rise in the global market for bispecific antibodies with the approval of Columvi for relapsed/refractory diffuse large B-cell lymphoma in June 2023. Being at the forefront of non-Hodgkin lymphoma treatment through groundbreaking bispecific such as Lunsumio contributes to the growth of the market.
Akeso is a biopharmaceutical company established in 2012 that focuses on developing affordable and creative antibody medications. Cadonilimab, a PD-1/CTLA-4 bispecific antibody, has shown positive results in treating stubborn solid tumors, expanding the potential market for bispecific antibodies.
Johnson & Johnson, an American pharmaceutical company, runs Janssen Pharmaceutical Company in New Brunswick, New Jersey. Janssen is at the forefront of the growth of the bispecific antibody market. Their groundbreaking treatments, such as TECVAYLI® and talquetamab, demonstrate a 96.3% response rate in multiple myeloma patients.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Immunocore Holdings plc, Eli Lilly and Company, and Genmab A/S.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Application |
|
| Breakup by Drugs |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share